Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping

Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping

Background: Approved treatments for colorectal cancer (CRC) patients pretreated with two lines of therapy are of limited efficacy. Anti-epidermal growth factor receptor (EGFR) re-challenge might represent an option in RAS wild-type tumours. This study aimed to evaluate the efficacy of anti-EGFR re-c...

Full description

Bibliographic Details
Main Authors: J. Sgouros, A. Eliades, K. Papadopoulou, N. Korfiatis, D. Papamichael, E. Fountzilas, E. Tsolaki, A. Achilleos, K. Tsangaras, C. Loizides, G. Oikonomopoulos, T. Makatsoris, E. Kypri, M. Ioannides, G. Koumbaris, G. Fountzilas, P.C. Patsalis, G. Pentheroudakis
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:ESMO Gastrointestinal Oncology
Subjects:
colorectal cancer
RAS wild type
anti-EGFR re-challenge
panitumumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2949819824000815

Internet

http://www.sciencedirect.com/science/article/pii/S2949819824000815

Similar Items